Triple–Receptor-Negative Breast Cancer: What We Know and Issues to Be Resolved
Triple–Receptor-Negative Breast Cancer: What We Know and Issues to Be Resolved
Carcinomas arising from the breast represent a heterogeneous group of tumors of distinct biologic subtypes that have been shown to be diverse in terms of response to therapy and prognostic outcomes. In an effort to understand this disease, further research has focused on characterizing breast tumor subtypes of known poor prognostic outcomes in order to define optimal therapeutic strategies to improve patient survival. Through gene-expression profiling, molecular subtypes of breast carcinomas have been identified (luminal, HER2-positive/estrogen receptor (ER)-negative, and basal like). The two hormone receptor–negative subtypes are associated with particularly poor outcomes compared to the hormone receptor–positive luminal subtypes.[1-4]
Approximately 10% to 15% of breast carcinomas are known to be “triple–receptor-negative” (ie, not expressing ER or progesterone receptors [PR] and not exhibiting overexpression and/or gene amplification of HER2/neu). Triple-negative breast cancers comprise approximately 85% of all basal-type tumors. As presented in the comprehensive article by Drs. Anders and Carey, a number of studies have focused on understanding the epidemiology, natural history, biology, and treatment strategies for this subtype.
What We Know Today
As clarified by Dr. Anders, it is important to define the terminology used. “Triple–receptor-negative” is a term based on established clinical immunohistochemical and fluorescence in situ hybridization assays for ER, PR, and HER2, whereas “basal-like” is a molecular phenotype defined by using cDNA microarrays.[1,3] When using transcriptional profiling, most triple-negative breast tumors cluster within the basal-like subgroup, but phenotypically there is about a 30% discordance between the two.[6-9] Despite consensus in this regard, most available evidence looks at only one of these groups, and the data are extrapolated to the other.
Epidemiologic findings now illustrate that breast cancer risk factors may vary by molecular subtype. More importantly, such observations are forcing us to reevaluate established breast cancer risk factors and prevention strategies. Important findings discussed in the Anders/Carey paper include the fact that compared to white women, young African-American women have a higher incidence of basal-like disease.[10,11] In addition, patients with basal-like breast tumors are more likely to be associated with an earlier age at menarche, younger age at full-term pregnancy, higher parity, shorter breast-feeding time, higher body mass index, and higher waist-to-hip ratio.[12,13]
Population-based studies have shown lower breast cancer–specific survival rates among those with triple-negative compared to non–triple-negative disease, as well as different patterns of recurrence. Patients with this disease are more likely to relapse during the first 3 years following therapy[14,15] and more commonly develop soft tissue and visceral relapses including CNS metastases. We reviewed a cohort of 679 women with early-stage triple-negative breast cancer in our institution and found that 6.2% of them developed brain metastases, more than half of whom had their first site of metastases located in the brain. As expected, survival following development of brain metastases was poor, with a median of 2.9 months (95% confidence interval [CI] = 2.0–7.6 months; data under review for publication).
Interestingly, despite the poor prognostic features, triple-negative breast cancer is sensitive to standard chemotherapeutic approaches including anthracycline- and taxane-based treatments.[14-17] However, some patients do not respond to standard therapy and have a dismal prognosis.. The discovery of certain molecular characteristics of triple-negative breast cancers is directing us to better understanding the pathophysiology of the disease and to developing more direct therapeutic strategies. It has been observed that most BRCA1-associated breast cancers are triple-negative, and that BRCA1 dysfunctions make cancer cells deficient in double-stranded DNA break repair mechanisms and sensitive to DNA damaging agents such us platinum salts and topoisomerase I inhibitors.[19,20]
Other promising targeted strategies being studied include EGFR-targeted agents, antiangiogenic agents, poly(ADP-ribose) polymerase (PARP) inhibitors, and PI3K pathway inhibitors. Although interesting results are coming from studies of these approaches, they have not yet replaced current standard therapy and should not be used in patients with curable disease outside a clinical trial.
We are fortunate that ongoing intense research will allow us to better understand this aggressive disease and hopefully to improve its outcome. Still, there are many questions that need to be solved. For example: How do we incorporate the molecular and epidemiologic data? Are all triple–receptor-negative breast cancers the same at the molecular level? Do African-American patients have the same prognosis as patients of other ethnicities once they are diagnosed with triple-negative disease? Are these breast cancers molecularly different among ethnic groups? If such differences in molecular characteristics and ethnicities exist, should therapeutic approaches be the same?
Investigators from different institutions are trying to solve some of these issues. Using transcriptional profiles to analyze human triple-negative breast cancers, researchers have found at least two molecularly different groups of tumors that appear to be associated with different outcomes (unpublished data).
In an effort to solve some of the ethnicity questions, we looked at 471 patients with triple-negative breast cancer treated with primary systemic chemotherapy to evaluate the effect of race on pathologic complete response (pCR) rates and survival outcomes. A total of 100 patients (21.2%) were classified as African-American. With treatment, 17% (n = 17) of African-American patients and 25.1% (n = 93) of white/other patients achieved a pCR (P = .091). The 3-year recurrence-free survival rates were 68% (95% CI = 56%–76%) and 62% (95% CI = 57%–67%) among African-American and white/other women, respectively, with no significant difference observed between the two groups (P = .302). The 3-year overall survival was similar between the two groups (71%, P = .919). After controlling for patient and tumor characteristics, race was not significantly associated with survival outcomes (data under review).
We have also started to look at genomic discrepancies between ethnicities in triple-negative breast cancer. We have analyzed the transcriptional profiles of 98 triple-negative tumors—19 belonged to African-American patients, 23 to Hispanic patients, and 56 to Caucasian women. We found no evidence of clustering of gene-expression data by ethnicity, or differentially expressed genes in triple-negative tumors among African-Americans compared to Caucasian or Hispanic women after adjustment for multiple comparisons.
These studies are just the beginning of attempts to better understand the epidemiologic and molecular characteristics of this disease. This is important, since in the absence of an understanding of the ethnic diversity of breast cancer, potential markers and targets specific to different populations could be missed.
Finally, ongoing clinical trials are being conducted in efforts to translate these molecular findings in both advanced and early disease to patient care. We are currently studying alternative chemotherapeutic agents such as platinum salts, topoisomerase inhibitors, and epothilones in the neoadjuvant setting. Multiple trials are studying agents targeting angiogenesis, PARP, EGFR, PI3K, and Src pathway inhibition, alone or in combination with chemotherapy in the (neo)adjuvant and metastatic settings.
All these studies will add to the current knowledge of triple–receptor-negative breast cancer. We must continue to identify the tumors that will respond to specific therapies, to develop biologic response modifiers that will improve cancer management, and to decrease the amount of time that it takes to deliver useful drugs to patients.
—Ana M. Gonzalez-Angulo, MD, MSC
—Gabriel N. Hortobagyi, MD
Financial Disclosure: The authors have no significant financial interest or other relationship with the manufacturers of any products or providers of any service mentioned in this article.
1. Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumors. Nature 406:747-752, 2000.
2. Sorlie T: Molecular portraits of breast cancer: Tumour subtypes as distinct disease entities. Eur J Cancer 40:2667-2675, 2004.
3. Sorlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869-10874, 2001.
4. Brenton JD, Carey LA, Ahmed AA, et al: Molecular classification and molecular forecasting of breast cancer: Ready for clinical application? J Clin Oncol 23:7350-7360, 2005.
5. Anders C, Carey LA: Understanding and treating triple-negative breast cancer. Oncology (Williston Park) 22:1233-1239, 2008.
6. Bertucci F, Finetti P, Cervera N, et al: How basal are triple-negative breast cancers? Int J Cancer 123:236-240, 2008.
7. Cleator S, Heller W, Coombes R: Triple-negative breast cancer: Therapeutic options. Lancet Oncol 3:235-244, 2007.
8. Kreike B, van Kouwenhove M, Horlings H, et al: Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 9:R65, 2007.
9. Nielsen T, Hsu F, Jensen K, et al: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10:5367-5374, 2004.
10. Ihemelandu CU, Lefall LD, Dewitty RL, et al: Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: Age-specific prevalence and survival. J Surg Res 143:109-118, 2007.
11. Carey L, Perou C, Livasy C, et al: Race, breast cancer subtypes, and survival in the carolina breast cancer study. JAMA 295:2492-2502, 2006.
12. Millikan RC, Newman B, Tse C-K, et al: Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 109:123-139, 2008.
13. Yang X, Sherman M, Rimm D, et al: Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 16:439-443, 2007.
14. Hayes N, Thor A, Dressler L, et al: HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357:1496-1506, 2007.
15. Smid M, Wang Y, Zhang Y, et al: Subtypes of breast cancer show preferential site of relapse. Cancer Res 68:3108-3114, 2008.
16. Carey L, Dees E, Sawyer L, et al: The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329-2334, 2007.
17. Rouzier R, Perou C, Symmans W, et al: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678-5685, 2005.
18. Liedtke C, Mazouni C, Hess K, et al: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275-1281, 2008.
19. Taniguchi T, Tischkowitz M, Ameziane N, et al: Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 9:568-574, 2003.
20. Turner N, Tutt A, Ashworth A: Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer 4:814-819, 2004.
21. Dean-Colomb W, Yan K, Liedtke C, et al: Transcriptional profiles of triple receptor-negative breast cancer: Are Caucasian, Hispanic, and African-American women different (abstract 22014)? J Clin Oncol 26(15S):750s, 2008.